<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="59586">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02330276</url>
  </required_header>
  <id_info>
    <org_study_id>08847</org_study_id>
    <secondary_id>1R01AT008310-01</secondary_id>
    <nct_id>NCT02330276</nct_id>
  </id_info>
  <brief_title>Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin</brief_title>
  <acronym>Epicatechin</acronym>
  <official_title>(+)-Epicatechin: Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Veterans Medical Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>San Diego Veterans Healthcare System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Veterans Medical Research Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Early Phase Pre-Clinical and Initial Clinical Research on (+)- Epicatechin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project is a double-blinded randomized Phase I study that will include dose-ranging one
      day PK and pharmacodynamic (PD) studies. Subjects will include healthy individuals and
      subjects who meet the American Diabetes Association (ADA) criteria for pre-diabetes,
      including IFG.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Levels of Epicatechin and Metabolites</measure>
    <time_frame>24 hours</time_frame>
    <description>Levels of epicatechin and metabolites present in circulation and urine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>9 Days</time_frame>
    <description>Number of Participants with Adverse Events as a Measure of Safety and Tolerability.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Pre-diabetes</condition>
  <arm_group>
    <arm_group_label>10 mg (+)-epicatechin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 subjects randomized to one dose of 10 mg (+)-epicatechin taken orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg (+)-epicatechin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 subjects randomized to one dose of 30 mg (+)-epicatechin taken orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg (+)-epicatechin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 subjects randomized to one dose of 100 mg (+)-epicatechin taken orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(+)-Epicatechin</intervention_name>
    <description>The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.</description>
    <arm_group_label>10 mg (+)-epicatechin</arm_group_label>
    <arm_group_label>30 mg (+)-epicatechin</arm_group_label>
    <arm_group_label>100 mg (+)-epicatechin</arm_group_label>
    <other_name>Epicatechin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy or pre-diabetic based on medical history

          -  Male or female

          -  Must be 21 to 75 years of age (inclusive)

          -  Able to give informed consent to the procedures

          -  If female, must be either postmenopausal or test negative for pregnancy at screening
             and on the day of the procedure. Women on estrogen therapy will be included.

          -  If of childbearing potential, must practice and be willing to continue to practice
             appropriate birth control during the entire duration of the study

          -  Medication use stable for 4 weeks

          -  Body Mass Index (BMI) &gt; 27 kg/m2

          -  Definition of pre-diabetes: impaired fasting glucose (IFG, fasting glucose = 100-125
             mg/dL) and elevated HbA1c (5.7-6.4%), each in the absence of other risk factors for
             diabetes

        Exclusion Criteria:

          -  Type 2 diabetes

          -  Pregnancy

          -  Younger than 21 or older than 75 years of age

          -  Clinically significant abnormalities in liver or kidney function (&gt;3x ULN),
             determined in the last 6 months by a certified clinical laboratory

          -  Recent MI or stroke (within 6 months of screening)

          -  Blood pressure (BP) &gt;160 mmHg Systolic and &gt;100 mmHg Diastolic

          -  Medications - thiazolidinediones, any steroids, anti-depressants, weight loss drugs

          -  Other diseases, besides type 2 diabetes, influencing carbohydrate metabolism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert R Henry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Diego Veterans Healthcare System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA San Diego Healthcare System</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>December 10, 2015</lastchanged_date>
  <firstreceived_date>December 23, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Veterans Medical Research Foundation</investigator_affiliation>
    <investigator_full_name>Robert R. Henry, MD</investigator_full_name>
    <investigator_title>Chief, Section of Diabetes, Endocrinology and Metabolism</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
